Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The use of cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) to guide treatment selection in metastatic breast cancer.

Pharmacogenomics - 1 Jan 2026

Bello Oluwaferanmi, Rieur Olivia, Vidula Neelima

Abstract excerpt

Metastatic breast cancer is a heterogeneous disease entity with varying genomic alterations. Mutations may be acquired through tumor evolution under the pressure of treatment. While both tumor tissue genotyping and cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) may be used to identify actionable mutations for therapeutic intervention, cfDNA/ctDNA offer the advantages of being less invasive and more feasible...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Neoplasms
Share to Cell-Free Nucleic Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to ERBB2 gene

Share to PIK3CA gene

Share to Mutation

Share to Neoplasm Metastasis

Source

Open in PubMed Open full text

Identifiers

PMID: 42002527
DOI: 10.1080/14622416.2026.2658438
PMCID: PMC13203047

Genes

BRCA1
ERBB2
ESR1
PIK3CA
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The use of cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) to guide treatment selection in metastatic breast cancer.PMID 42002527Read ↗

A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.Semantic proximity Read ↗

Multimodal Targeted Deep Sequencing of Circulating Tumor Cells and Matched Cell-Free DNA Provides a More Comprehensive Tool to Identify Therapeutic Targets in Metastatic Breast Cancer PatientsSemantic proximity Read ↗

Circulating free DNA in the era of precision oncology: Pre‐ and post‐analytical concernsSemantic proximity Read ↗

Diagnostic and Therapeutic Potential of Circulating-Free DNA and Cell-Free RNA in Cancer ManagementSemantic proximity Read ↗

Cell-free DNA (cfDNA): Clinical Significance and Utility in Cancer Shaped By Emerging TechnologiesSemantic proximity Read ↗

Comprehensive Genomic Profiling of Cell-Free Circulating Tumor DNA Detects Response to Ribociclib Plus Letrozole in a Patient with Metastatic Breast Cancer.Semantic proximity Read ↗

High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.Semantic proximity Read ↗

The applications of plasma cell-free DNA in cancer detection: Implications in the management of breast cancer patients.Semantic proximity Read ↗

Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary DiseaseSemantic proximity Read ↗

Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patientsSemantic proximity Read ↗

Exploring the Role of Circulating Cell-Free DNA in Disease Diagnosis and TherapySemantic proximity Read ↗

Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.